Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses.
To design combination strategies for chronic hepatitis B therapy, we evaluated in vitro the inhibitory activity of 4 nucleoside analogs, (-)FTC, L-FMAU, DXG, and DAPD, in comparison with lamivudine (3TC) and PMEA. In a cell-free assay for the expression of wild-type duck hepatitis B virus (DHBV) reverse transcriptase, DAPD-TP was found to be the most active on viral minus strand DNA synthesis, including the priming reaction, followed by 3TC-TP, (-)FTC-TP, and DXG-TP, whereas L-FMAU-TP was a weak inhibitor. In cell culture experiments, important differences in drug concentration allowing a 50% inhibition of viral replication or polymerase activity (IC50s) were observed depending on the cell type used, showing that antiviral effect of nucleoside analogs may depend on their intracellular metabolism. IC50s obtained for wild-type DHBV replication in primary duck hepatocytes were much lower than with DHBV transfected LMH cells. IC50s were also significantly lower in the 2.2.1.5 and HepG2 cells compared with HBV transfected HuH7 cells. Moreover, L-FMAU inhibited preferentially HBV plus strand DNA synthesis in these cell lines. The antiviral effect of these inhibitors was also evaluated against 3TC-resistant mutants of the DHBV and HBV polymerases. These mutants were found to be cross resistant to (-)FTC. By contrast, the double DHBV polymerase mutant was sensitive to DXG-TP and DAPD-TP. Moreover, both purine analogs remained active against DHBV and HBV 3TC-resistant mutants in transfected LMH and HepG2 cells, respectively. In conclusion, the unique mechanism of action of these new inhibitors warrants further evaluation in experimental models to determine their capacity to delay or prevent the selection of drug resistant mutants.
INSERM Unit 271, Lyon, France.
Béatrice
B
Seignères
Christian
C
Pichoud
Perrine
P
Martin
Philip
P
Furman
Christian
C
Trépo
Fabien
F
Zoulim
D000818:Animals; D001085:Arabinofuranosylcytosine Triphosphate / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology; D001086:Arabinofuranosyluracil / Q000031:analogs & derivatives / Q000737:chemistry / Q000494:pharmacology; D006528:Carcinoma, Hepatocellular; D003570:Cytidine Triphosphate / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology; D004261:DNA Replication / Q000187:drug effects; D004279:DNA, Viral / Q000235:genetics; D004259:DNA-Directed DNA Polymerase / Q000378:metabolism; D004148:Dioxolanes / Q000737:chemistry / Q000494:pharmacology*; D024882:Drug Resistance, Viral; D015967:Gene Expression Regulation, Viral / Q000187:drug effects; D006151:Guanosine / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology; D018347:Hepadnaviridae Infections / Q000188:drug therapy*; D015611:Hepatitis B Virus, Duck / Q000235:genetics*; D006515:Hepatitis B virus; D006524:Hepatitis, Viral, Animal / Q000188:drug therapy*; D022781:Hepatocytes / Q000166:cytology / Q000821:virology; D006801:Humans; D019259:Lamivudine / Q000494:pharmacology; D008113:Liver Neoplasms; D009154:Mutation; D011684:Purine Nucleosides / Q000737:chemistry / Q000494:pharmacology*; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology; D013876:Thiophenes; D014407:Tumor Cells, Cultured
D004279:DNA, Viral; D004148:Dioxolanes; D011684:Purine Nucleosides; D018894:Reverse Transcriptase Inhibitors; D013876:Thiophenes; C098394:dioxolane guanosine; D006151:Guanosine; D001085:Arabinofuranosylcytosine Triphosphate; C083567:5-fluoro-1-(2-hydroxymethyl)-1,3-oxathiolane-5-yl-cytidine-5'-triphosphate; D019259:Lamivudine; D001086:Arabinofuranosyluracil; C098393:amdoxovir; D003570:Cytidine Triphosphate; C047247:1-(2'-deoxy-2'-fluoro-beta-arabinofuranosyl)-5-methylcytosine triphosphate; D004259:DNA-Directed DNA Polymerase; C034935:clevudine